ĐÁNH GIÁ THỜI GIAN SỐNG THÊM TOÀN BỘ CỦA PHÁC ĐỒ XELOX BỔ TRỢ TRÊN BỆNH NHÂN UNG THƯ DẠ DÀY TẠI BỆNH VIỆN VIỆT ĐỨC

Abstract

Objective: To evaluate the overall survival time and some influencing factors of the adjuvant XELOX regimen in gastric cancer patients at Viet Duc Friendship Hospital. Subjects and methods: A descriptive study with longitudinal follow-up was conducted on 65 patients with stage IB–IIIC gastric cancer who underwent radical surgery and adjuvant chemotherapy with the XELOX (CAPOX) regimen from January 2017 to June 2021. Results: The overall survival rates after 1, 3 and 5 years were 96.9%, 71.8% and 53.1%, respectively, with a median survival time of 55.9 months (CI 95%: 50.8–61.0). The overall 5-year survival rate in the moderately differentiated adenocarcinoma group (72.7%) compared with the poorly differentiated (51.1%) and signet ring cell (48.2%) groups with p=0.034. The group with neurovascular invasion had a statistically significant lower 5-year survival time and overall survival rate (p=0.001). The overall 5-year survival rate decreased gradually with the progression of the disease stage with p<0.001. Conclusion: The XELOX regimen is an effective and well-tolerated adjuvant treatment for patients with stage IB–IIIC gastric cancer after radical surgery.